|Medtronic Valiant Captivia Demonstrates Safety and Efficacy at Three Years|
New Clinical Data Presented in Complicated Type B Aortic Dissection at VIVA 2016
DUBLIN and LAS VEGAS - Sept. 20, 2016 - Medtronic plc (NYSE: MDT) today announced new data, demonstrating safety and efficacy at three years in acute complicated Type B aortic dissection patients treated with the Valiant® Captivia® Thoracic Stent Graft System. Ali Azizzadeh, MD, FACS, University of Texas Health Science Center in Texas presented the new clinical data in a late-breaking trial session at Vascular Interventional Advances (VIVA) 2016.
An acute aortic dissection is a serious condition in which the inner layer of the aorta tears, blood surges through the tear, and causes the inner and middle layers of the aorta to separate. This can result in aorta rupture or malperfusion of the vessels originating from the dissected aorta, leading to high morbidity and mortality. A type B dissection is a tear located in the descending aorta.
"Evidence shows that patients with acute complicated Type B aortic dissections can be safely and effectively treated with thoracic endovascular aortic repair (TEVAR)," said Dr. Azizzadeh. "The Valiant Captivia System continues to produce positive outcomes through three years in a very challenging patient population."
The FDA-approved Valiant Captivia System demonstrates continued safety and efficacy at three years. The data were gathered on 50 patients in the Medtronic Valiant Captivia Dissection IDE Trial, conducted at 16 U.S. sites.
Data highlights through three-year follow-up:
"Medtronic is committed to working with physicians to treat more complex aortic disease and improve the lives of patients," said Daveen Chopra, vice president and general manager of the Aortic business, which is part of the Aortic & Peripheral Vascular division at Medtronic. "The Valiant line of technology leverages decades of clinical experience in continuing to treat thoracic disease and has been used to treat more than 75,000 patients."
In collaboration with leading clinicians, researchers, and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services of the highest quality that deliver clinical and economic value to healthcare consumers and providers around the world.
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 88,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.